Happy Independence Day! We wish everyone a safe, celebratory, and fun holiday to mark our nation’s independence. #OneLexeo
Lexeo Therapeutics
Biotechnology Research
New York, New York 9,031 followers
Advancing science with curative potential for both cardiovascular and APOE4 associated Alzheimer's disease areas.
About us
Based in New York City, Lexeo Therapeutics is a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Building on groundbreaking research from Weill Cornell Medicine and the University of California San Diego, Lexeo partners with preeminent institutions on the cutting edge of gene therapy research. Using a stepwise development approach, Lexeo is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4 associated Alzheimer's disease programs, and is led by pioneers and experts with decades of collective experience in genetic medicines, rare disease drug development, manufacturing and commercialization. For more information, please visit www.lexeotx.com.
- Website
-
http://www.lexeotx.com
External link for Lexeo Therapeutics
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- New York, New York
- Type
- Privately Held
- Founded
- 2018
Locations
-
Primary
345 Park Avenue South
6th Floor
New York, New York 10010, US
Employees at Lexeo Therapeutics
Updates
-
We're excited to feature our VP of clinical development, cardiology, Franca A., MD, PhD in our latest Employee Spotlight! Franca is a key member of our team, bringing passion and dedication to her work in cardiology. Her commitment to innovation and patient care exemplifies the values we hold at Lexeo. Check out the below to learn more about Franca. #OneLexeo
-
Arrhythmogenic cardiomyopathy (ACM), a genetic heart disease, is characterized by changes to the heart muscle, which affect its electrical activity. This condition leads to scarring, heart dysfunction and, in severe cases, sudden death. In the US, an estimated 130,000 individuals are affected, and more than half having a genetic cause, primarily associated with mutations in the PKP2 gene. At Lexeo, we are developing a number of disease-modifying gene therapy candidates to treat cardiovascular diseases with significant unmet need. Our investigational AAV-based gene therapy LX2020, is being evaluated to deliver a fully functional PKP2 gene to heart muscle for the treatment of PKP2-ACM. Learn more about our AAV-based gene therapy candidate, LX2020: https://lnkd.in/gNWDX9aQ
-
-
Congratulations to Sarepta Therapeutics on receiving FDA's full approval of their gene therapy for ambulatory Duchenne muscular dystrophy (DMD) in patients four years or older. This is a critical milestone for patients with DMD and their loved ones, and it underscores the importance of accelerated approval as a potential path to get more cell and gene therapies to patients more quickly, especially when unmet needs are high and current treatments do not fully address them. We are excited to see this progress for patients, and within the field, as we work to realize the full potential of genetic medicines.
-
Today, all of us at Lexeo join the nation in commemorating #Juneteenth. We are dedicated to advancing equity for all, and fostering a future where every voice is heard, and every individual is valued. Do you know the story of #Juneteenth? Learn more and join in the celebration with Smithsonian's National Museum of African American History and Culture: nmaahc.si.edu/Juneteenth
-
-
Happy #PrideMonth! Lexeo proudly stands in solidarity with the #LGBTQ+ community. We are committed to cultivating an inclusive work environment for all. #OneLexeo #Pride
-
-
June marks Alzheimer’s & Brain Awareness Month. Did you know that the risk of developing Alzheimer’s disease may be influenced by your genes? People who are APOE4 homozygous, meaning they have two copies of a gene variant called APOE4, are approximately 15 times more likely to develop Alzheimer’s. Lexeo is developing CNS-focused gene therapies to address the underlying genetic cause of APOE4-associated Alzheimer’s disease. Learn more about our programs here: https://lnkd.in/g2BGvuSM #ENDALZ #ALZScience
-
-
Our leadership team truly valued the opportunity to connect professionally and personally during a recent offsite. We focused on how we can potentially bring #genetherapy candidates to patients more quickly and discussed how Lexeo values can bolster our day-to-day culture and organizational goals. We also had time for some fun! Check out some of our photos! #OneLexeo
-
As we close out #FAAwarenessMonth, we want to take a moment and commemorate the incredible network of individuals, families, researchers and advocates in the Friedreich ataxia (FA) community. Last week, we were fortunate to host Jen Farmer, CEO of the Friedreich's Ataxia Research Alliance (FARA), along with members of the FA community, at our New York office. Colleagues learned more about the important work FARA is doing in FA and heard important perspectives from a patient and caregivers about their journeys. It was inspiring to hear from the FA community directly, and it reinforced our commitment to the patient community. #FriedreichAtaxia #RareDisease #OneLexeo
-
-
We are delighted to welcome José Manuel (Manny) Otero as the new Chief Technical Officer (CTO) of Lexeo. With a wealth of experience in bioprocess development, manufacturing, and clinical-stage therapeutics, Manny will lead our CMC and technical operations team as we work to advance #genetherapy research. Join us in welcoming Manny to #Lexeo!
-